Media release

From: Hab Shifa

Study into thymoquinone holds immune-system hope for Australians

Australian manufacturer of black seed (Nigella sativa L.) oil supplements, Hab Shifa, has successfully completed phase-one of its study into improved thymoquinone (TQ) extraction from black seed.

The oil extraction and separation study was completed by CSIRO, Australia’s national science agency, comparing various technologies for extraction and concentration of TQ from black seeds.

TQ is indicated in supporting blood sugar modulation in healthy individuals. Further clinical indications for TQ include supporting healthy cholesterol levels, cardiovascular system in healthy individuals, as well as supporting immune system function and relieving symptoms of the common cold.

Hab Shifa Founder, Azam Kassim, says that the phase-one study explored increasing the amount of TQ that could be extracted from black seed while protecting its quality and bioavailability. The goal is to produce a more effective and bioavailable compound for use in supplements.

“We are excited to announce that our phase-one results showed that up to 25% concentration of TQ could be extracted, which is dramatically higher than current extraction levels of 0.75-1.5%” Mr Kassim says. “We were also able to achieve environmental sustainability, scalability and cost effectiveness.”

“Now, we are planning to commence our phase-two investigation into how this more concentrated version of TQ black seed oil can support anti-inflammatory, antioxidant and anti-age effects on individuals.”

With phase-one now complete, a phase-two study with NICM Health Research Institute, Western Sydney University is imminent. Phase-two will explore how the improved TQ compound impacts anti-inflammatory, anti-oxidative and anti-ageing activity in humans.

For more information, visit: www.habshifa.com.au.